Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

Oncoimmunology. 2012 Sep 1;1(6):997-999. doi: 10.4161/onci.19865.

Abstract

Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.